Elegance in Molecular Design
Bi-specific, single agent
small molecule treatments
FLAG Therapeutics is developing a first-in-class, dual-acting, small molecule for the treatment of glioblastoma. FLAG-003 is a water-soluble, hybrid-scaffold elegantly designed to target cancer cells. With a unique dual mechanism of action, FLAG-003 is small enough to pass the blood-brain-barrier and is engineered to simultaneously block the formation of new blood vessels and kill cancer cells.
*FLAG-003 is currently under investigational use.
Awarded $1.5 M 2 year SBIR to study Purine Synthesis Inhibitors for the treatment of Mesothelioma
Successful pre-IND meeting with US FDA for FLAG-003
FLAG granted Orphan Drug Designation for FLAG-003 for the treatment of Glioma in both the US and EU.
Interested in FLAG's technology? Please send us a message and we'll be in touch.